Recent NIMH clinical trials and implications for practice.
Vitiello
Benedetto
B
National Institute of Mental Health, Bethesda, MD 20892-9633, USA. bvitiell@mail.nih.gov
D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D001521:Behavior Therapy; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000628:therapy; D002675:Child, Preschool; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003511:Cyclohexanols / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000628:therapy; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D001523:Mental Disorders / Q000628:therapy*; D008774:Methylphenidate / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009315:National Institute of Mental Health (U.S.); D009771:Obsessive-Compulsive Disorder / Q000628:therapy; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D020280:Sertraline / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States; D000069470:Venlafaxine Hydrochloride
D000697:Central Nervous System Stimulants; D003511:Cyclohexanols; D003692:Delayed-Action Preparations; D005473:Fluoxetine; D008774:Methylphenidate; D011619:Psychotropic Drugs; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D000069470:Venlafaxine Hydrochloride